Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Skye Bioscience ( (SKYE) ) has issued an update.
On October 6, 2025, Skye Bioscience announced the topline data from its 26-week Phase 2a CBeyond study of nimacimab, a CB1 inhibitor antibody. The study revealed that nimacimab monotherapy did not meet its primary endpoint for weight loss due to lower than expected drug exposure, suggesting the need for higher dosing. However, the combination of nimacimab with semaglutide showed a clinically meaningful additional weight loss compared to semaglutide alone, with a favorable safety profile. This outcome supports further studies to evaluate the combination’s potential in obesity treatment.
The most recent analyst rating on (SKYE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Skye Bioscience stock, see the SKYE Stock Forecast page.
Spark’s Take on SKYE Stock
According to Spark, TipRanks’ AI Analyst, SKYE is a Underperform.
Skye Bioscience’s overall stock score is primarily hindered by significant financial challenges, including zero revenue and continuous losses. Despite strong earnings call highlights and a substantial cash position, the bearish technical analysis and valuation difficulties weigh heavily on the score.
To see Spark’s full report on SKYE stock, click here.
More about Skye Bioscience
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing new therapeutic pathways for obesity and other metabolic health disorders.
Average Trading Volume: 386,555
Technical Sentiment Signal: Buy
Current Market Cap: $147.2M
For a thorough assessment of SKYE stock, go to TipRanks’ Stock Analysis page.